• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

2009-2021 年德国恶性胰腺神经内分泌肿瘤患者的发病率和生存率。

Incidence and survival of patients with malignant pancreatic neuroendocrine neoplasms in Germany, 2009-2021.

机构信息

Institute of Medical Informatics, Biometry and Epidemiology, University Hospital Essen, Germany; School of Public Health, Department of Epidemiology, Boston University, Boston, USA; Cancer Registry of North Rhine-Westphalia, Bochum, Germany.

Cancer Registry of North Rhine-Westphalia, Bochum, Germany.

出版信息

Cancer Epidemiol. 2024 Dec;93:102659. doi: 10.1016/j.canep.2024.102659. Epub 2024 Sep 6.

DOI:10.1016/j.canep.2024.102659
PMID:39243580
Abstract

BACKGROUND

Due to the rarity of pancreatic neuroendocrine neoplasms, only few population-representative studies on incidence and survival have been conducted. The aim was to provide up-to-date nationwide incidence and relative survival estimates of neuroendocrine (NE) neoplasms overall, NE tumors (NETs), NE carcinomas (NECs), and mixed NE neoplasms (MiNEN).

METHODS

We distinguished between pancreatic NETs (functioning versus non-functioning), NECs and mixed NE neoplasms and analyzed data from 2009 through 2021 from all German cancer registries covering a population of more than 80 million. We calculated crude and age-standardized incidence rates and 5-year relative survival estimates (RS).

RESULTS

Overall 6474, 4217, and 243 patients with pancreatic NETs, NECs, and mixed NE neoplasms, respectively were registered. While the age-standardized incidence of NETs has increased (+16.4 % per year, 95 %CI 12.2;20.7), the incidence of NEC has fallen (about -6.4 % per year, 95 %CI -8.0; -4.8). The crude RS was 77.7 % (standard error [SE] 0.9) for non-functioning NETs, 90.3 % for functioning NETs (SE 3.9), and 18.5 % (SE 3.9) for MiNEN. Large and small cell NECs had a low RS (9.1 % and 6.9 %, respectively). RS for G1 NETs was 88.2 %, while it was only 36.6 % for G3 NETs. Localized NETs had a RS of 92.8 %, while distant metastatic NETs had a RS of 45.0 %.

CONCLUSIONS

The incidence of pancreatic NETs has increased markedly in Germany in the period 2009-2021. Subgroups of NETs (G1 grading or localized stage) have an excellent prognosis. RS of MiNEN is more similar to NECs than NETs.

摘要

背景

由于胰腺神经内分泌肿瘤罕见,仅有少数基于人群的关于发病率和生存率的研究。本研究旨在提供最新的全国范围内神经内分泌(NE)肿瘤、NE 肿瘤(NETs)、NE 癌(NECs)和混合 NE 肿瘤(MiNEN)的发病率和相对生存率估计。

方法

我们区分了胰腺 NETs(功能性与非功能性)、NECs 和混合 NE 肿瘤,并分析了 2009 年至 2021 年期间来自覆盖 8000 多万人口的所有德国癌症登记处的数据。我们计算了粗发病率和年龄标准化发病率以及 5 年相对生存率(RS)。

结果

共登记了 6474 例胰腺 NETs、4217 例 NECs 和 243 例混合 NE 肿瘤患者。NETs 的年龄标准化发病率增加(每年增加 16.4%,95%CI 12.2%;20.7%),而 NEC 的发病率下降(每年下降约 6.4%,95%CI -8.0%;-4.8%)。非功能性 NETs 的粗 RS 为 77.7%(标准误差 [SE] 0.9),功能性 NETs 为 90.3%(SE 3.9),MiNEN 为 18.5%(SE 3.9)。大细胞和小细胞 NEC 的 RS 较低(分别为 9.1%和 6.9%)。G1 NETs 的 RS 为 88.2%,而 G3 NETs 的 RS 仅为 36.6%。局限性 NETs 的 RS 为 92.8%,而远处转移的 NETs 的 RS 为 45.0%。

结论

2009-2021 年期间,德国胰腺 NETs 的发病率显著增加。NETs 的亚组(G1 分级或局部阶段)具有极好的预后。MiNEN 的 RS 更类似于 NECs 而不是 NETs。

相似文献

1
Incidence and survival of patients with malignant pancreatic neuroendocrine neoplasms in Germany, 2009-2021.2009-2021 年德国恶性胰腺神经内分泌肿瘤患者的发病率和生存率。
Cancer Epidemiol. 2024 Dec;93:102659. doi: 10.1016/j.canep.2024.102659. Epub 2024 Sep 6.
2
Incidence and relative survival of pancreatic adenocarcinoma and pancreatic neuroendocrine neoplasms in Germany, 2009-2018. An in-depth analysis of two population-based cancer registries.德国 2009-2018 年胰腺腺癌和胰腺神经内分泌肿瘤的发病率和相对生存率。两个基于人群的癌症登记处的深入分析。
Cancer Epidemiol. 2022 Aug;79:102204. doi: 10.1016/j.canep.2022.102204. Epub 2022 Jun 28.
3
Survivals of patients with pancreatic neuroendocrine carcinomas: An in-depth analysis by the American Joint Committee on Cancer 8th tumor-node-metastasis staging manual.胰腺神经内分泌癌患者的生存情况:美国癌症联合委员会第8版肿瘤-淋巴结-转移分期手册的深入分析
Medicine (Baltimore). 2020 Jan;99(3):e18736. doi: 10.1097/MD.0000000000018736.
4
Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE).神经内分泌肿瘤异质性给 2010 年世界卫生组织分类带来不确定性:来自西班牙肿瘤登记处(R-GETNE)的真实世界数据。
Oncologist. 2018 Apr;23(4):422-432. doi: 10.1634/theoncologist.2017-0364. Epub 2018 Jan 12.
5
World Health Organization grading classification for pancreatic neuroendocrine neoplasms: a comprehensive analysis from a large Chinese institution.世界卫生组织胰腺神经内分泌肿瘤分级分类:来自中国大型医疗机构的综合分析。
BMC Cancer. 2020 Sep 22;20(1):906. doi: 10.1186/s12885-020-07356-5.
6
Incidence trends of lung and gastroenteropancreatic neuroendocrine neoplasms in Switzerland.瑞士肺和胃肠胰神经内分泌肿瘤的发病趋势。
Cancer Med. 2020 Dec;9(24):9454-9461. doi: 10.1002/cam4.3524. Epub 2020 Oct 20.
7
A Consensus-Developed Morphological Re-Evaluation of 196 High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms and Its Clinical Correlations.196例高级别胃肠胰神经内分泌肿瘤的形态学重新评估共识及其临床相关性
Neuroendocrinology. 2021;111(9):883-894. doi: 10.1159/000511905. Epub 2020 Oct 1.
8
Recent epidemiology of patients with gastro-entero-pancreatic neuroendocrine neoplasms (GEP-NEN) in Japan: a population-based study.日本胃-肠-胰神经内分泌肿瘤(GEP-NEN)患者的最新流行病学:一项基于人群的研究。
BMC Cancer. 2020 Nov 14;20(1):1104. doi: 10.1186/s12885-020-07581-y.
9
Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States.美国神经内分泌肿瘤患者的发病率、患病率和生存结局趋势。
JAMA Oncol. 2017 Oct 1;3(10):1335-1342. doi: 10.1001/jamaoncol.2017.0589.
10
Exploring the expression of DLL3 in gastroenteropancreatic neuroendocrine neoplasms and its potential diagnostic value.探讨DLL3在胃肠胰神经内分泌肿瘤中的表达及其潜在诊断价值。
Sci Rep. 2025 Jan 26;15(1):3287. doi: 10.1038/s41598-025-86237-y.

引用本文的文献

1
Prognostic Features in Surgically Resected Well-Differentiated Pancreatic Neuroendocrine Tumors: an Analysis of 904 Patients with 7882 Person-Years of Follow-Up.手术切除的高分化胰腺神经内分泌肿瘤的预后特征:对904例患者进行7882人年随访的分析
Endocr Pathol. 2025 Jun 27;36(1):24. doi: 10.1007/s12022-025-09866-z.
2
Prognosis of NETs: Has There Been Improvement over the Last 30 Years?神经内分泌肿瘤的预后:在过去30年里有改善吗?
Neuroendocrinology. 2025 May 30:1-13. doi: 10.1159/000546613.
3
Prognostic Features in Surgically Resected Well-Differentiated Pancreatic Neuroendocrine Tumors: An Analysis of 904 Patients with 7882 Person-Years of Follow-Up.
手术切除的高分化胰腺神经内分泌肿瘤的预后特征:对904例患者进行7882人年随访的分析
medRxiv. 2025 Apr 3:2025.04.01.25325055. doi: 10.1101/2025.04.01.25325055.
4
Diagnostic and prognostic biomarkers for pancreatic neuroendocrine neoplasms.胰腺神经内分泌肿瘤的诊断和预后生物标志物
Pathologie (Heidelb). 2024 Nov;45(Suppl 1):74-82. doi: 10.1007/s00292-024-01393-8. Epub 2024 Nov 18.